Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1780Triple Negative Breast Neoplasms 299Ovarian Neoplasms 136Lung Neoplasms 115Colorectal Neoplasms 115Neoplasms 106Prostatic Neoplasms 103Carcinoma, Non-Small-Cell Lung 101Neoplasm Metastasis 96Stomach Neoplasms 81Pancreatic Neoplasms 78Melanoma 74Endometrial Neoplasms 65Head and Neck Neoplasms 60Uterine Cervical Neoplasms 56Squamous Cell Carcinoma of Head and Neck 50Colonic Neoplasms 45Esophageal Neoplasms 42Sarcoma 41Carcinoma, Intraductal, Noninfiltrating 41Motor Activity 37HER2-positive Breast Cancer 34Urinary Bladder Neoplasms 33Liver Neoplasms 31Carcinoma, Renal Cell 30Brain Neoplasms 28Advanced Breast Cancer 25Lymphedema 24Kidney Neoplasms 24Carcinoma, Transitional Cell 23

Interventions

Letrozole 2exemestane 1dalpiciclib 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × HR Positive HER2 Negative Advanced Breast Cancer × Breast × Clear all
NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
120 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡